Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Sells 8,976 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 8,976 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the transaction, the chief operating officer now directly owns 131,636 shares of the company’s stock, valued at approximately $4,529,594.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87.
• On Monday, June 24th, Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $36.59 on Friday. The firm’s fifty day moving average price is $41.07 and its 200 day moving average price is $33.61. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $47.45. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of -9.22 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, August 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its position in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after acquiring an additional 669 shares during the last quarter. Amalgamated Bank boosted its stake in shares of Dyne Therapeutics by 39.9% during the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Dyne Therapeutics by 28.0% during the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after buying an additional 1,291 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new position in Dyne Therapeutics in the 2nd quarter valued at about $203,000. Finally, Farallon Capital Management LLC purchased a new stake in Dyne Therapeutics during the 2nd quarter valued at approximately $212,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. JPMorgan Chase & Co. lifted their target price on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. Morgan Stanley boosted their price objective on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Oppenheimer restated an “outperform” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Finally, Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $51.40.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.